Background: Diabetes mellitus (DM) is associated with long-term damage, dysfunction, of various organs. Objectives: Study aims to assess the role of new Synthesized Flavonoid compound on experimentally induced diabetes. Methods: 50 adult male albino rats divided  into 5 groups. Group 1 (control group, rats were orally administered with 1 ml saline daily). Group 2 (DMSO group, rats were orally administered with 0.2 % DMSO for 60 day orally). Group 3 (positive control, animals were injected intraperitoneally with 60 mg/kg b.wt streptozotocin followed by intraperitoneal injection with 120 mg/kg b.wt of Nicotinamide after 15 minute).Group 4 (standard group, diabetic  animals treated  with 100 mg/kg b.wt of  metformin  for 60 day orally). Group 5 (therapeutic group, diabetic rats treated  with 50 mg /kg  b.wt of Ethyl 2-amino-4-phenyl-4H-benzo(h)chromene-3-carboxylate for  60 day orally). At the end of experimental period blood serum & plasma samples, liver, kidney and pancreatic tissues were collected. Results: diabetic rats showed significant increase in  plasma glucose,  serum urea, creatinine, cholesterol and triglyceride . Also  significant increase in mean level of Fetuin A and Netrin-1 in serum and different organs (Liver, kidney, Pancreas) in compared to control group. Oral administration of Ethyl 2-amino-4-phenyl-4H-benzo(h)chromene-3-carboxylate cause decrease in elevated  biochemical parameters. Also, decrease Fetuin A and Netrin-1  levels when  compared with diabetic rats. Molecular docking studies confirmed binding of compound with Fetuin A and Netrin-1 proteins  in terms of energy and  revealed of the existence of hydrogen bond ,hydrophobic interaction,Our results were confirmed by histopathological examination of pancreatic tissue. Conclusion: this study suggests that Ethyl 2-amino-4-phenyl-4H-benzo(h)chromene-3-carboxylate exihibits  antihyperglycemic  activity in  streptozotocin- induced  diabetic  rats.